Press Releases

Date Title and Summary View
January 24, 2018 Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Richard F.
View HTML
January 2, 2018 Eleven Biotherapeutics to Present at Biotech Showcase 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
December 13, 2017 Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 13, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Dr.
View HTML
November 30, 2017 Eleven Biotherapeutics to Present at the LD Micro Main Event 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 30, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
November 20, 2017 Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results
-- Phase 3 Enrollment on Track to Complete in Q1 2018 -- -- Topline 3-Month Data from Phase 3 Trial of Vicinium™ on Track for Mid-2018 -- -- Strengthened Balance Sheet with $8.0 million Capital Raise -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2017-- Eleven Biotherapeutics, Inc.
View HTML
November 9, 2017 Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will host a live conference call and webcast at
View HTML
November 9, 2017 Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
November 3, 2017 Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering
CAMBRIDGE, Mass --(BUSINESS WIRE)--Nov. 3, 2017-- Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the closing of the
View HTML
November 1, 2017 Eleven Biotherapeutics Prices of $8.0 Million Underwritten Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2017-- Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the pricing of an
View HTML
October 13, 2017 Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
-- Brings extensive capital raising and transaction experience to Eleven’s management team -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 13, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein
View HTML